Korean Circulation Journal

The Korean Society of Cardiology (대한심장학회)
권호 표지
DOI QR코드

DOI QR Code

Antithrombotic or Anti-Platelet Agents in Patients Undergoing Permanent Pacemaker Implantation

  • Lee, Chang-Kun (Division of Cardiology, Department of Internal Medicine, University of Ulsan College of Medicine, Gangneung Asan Hospital) ;
  • Yoo, Sang-Yong (Division of Cardiology, Department of Internal Medicine, University of Ulsan College of Medicine, Gangneung Asan Hospital) ;
  • Hong, Man-Yong (Division of Cardiology, Department of Internal Medicine, University of Ulsan College of Medicine, Gangneung Asan Hospital) ;
  • Jang, Jin-Kun (Division of Cardiology, Department of Internal Medicine, University of Ulsan College of Medicine, Gangneung Asan Hospital)
  • Published : 2012.08.31
⟨ Previous Next ⟩

Abstract

Background and Objectives: The growing implantations of electrophysiological devices in the context of increasing rates of chronic antithrombotic therapy in cardiovascular disease patients underscore the importance of an effective periprocedural prophylactic strategy for prevention of bleeding complications. We assessed the risk of significant bleeding complications in patients receiving anti-platelet agents or anticoagulants at the time of permanent pacemaker (PPM) implantation. Subjects and Methods: We reviewed bleeding complications in patients undergoing PPM implantation. The use of aspirin or clopidogrel was defined as having taking drugs within 5 days of the procedure and warfarin was changed to heparin before the procedure. A significant bleeding complication was defined as a bleeding incident requiring pocket exploration or blood transfusion. Results: Permanent pacemaker implantations were performed in 164 men and 96 women. The mean patient age was $73{\pm}11$ years old. Among the 260 patients, 14 patients took warfarin (in all of them, warfarin was changed to heparin at least 3 days before procedure), 54 patients took aspirin, 4 patients took clopidogrel, and 25 patients took both. Significant bleeding complications occurred in 8 patients (3.1%), all of them were patients with heparin bridging (p<0.0001). Heparin bridging markedly increased the length of required hospital stay when compare with other groups and the 4 patients (1.5%) that underwent the pocket revision for treatment of hematoma. Conclusion: This study suggests that hematoma formation after PPM implantation was rare, even among those who had taken the anti-platelet agents. The significant bleeding complications frequently occurred in patients with heparin bridging therapy. Therefore, heparin bridging therapy was deemed as high risk for significant bleeding complication in PPM implantation.

Keywords

References

  1. Gupta A, Halleran SM, Krishnan K, Trohman RG. Rescue permanent iliac vein pacing after epicardial lead failure: an unusual reversal of pacing fortune. Europace 2008;10:1236-8. https://doi.org/10.1093/europace/eun185
  2. Moss AJ, Zareba W, Hall WJ, et al. Prophylactic implantation of a defibrillator in patients with myocardial infarction and reduced ejection fraction. N Engl J Med 2002;346:877-83. https://doi.org/10.1056/NEJMoa013474
  3. Lee GY, Chang BS, Song JU, et al. Deglutition syncope associated with ventricular asystole in a patient with permanent atrial fibrillation. Korean Circ J 2010;40:99-101. https://doi.org/10.4070/kcj.2010.40.2.99
  4. Lee CK, Shin DH, Jang JK, et al. Progressive familial heart block type I in a Korean patient. Korean Circ J 2011;41:276-9. https://doi.org/10.4070/kcj.2011.41.5.276
  5. Maree AO, Fitzgerald DJ. Variable platelet response to aspirin and clopidogrel in atherothrombotic disease. Circulation 2007;115:2196-207. https://doi.org/10.1161/CIRCULATIONAHA.106.675991
  6. Giudici MC, Paul DL, Bontu P, Barold SS. Pacemaker and implantable cardioverter defibrillator implantation without reversal of warfarin therapy. Pacing Clin Electrophysiol 2004;27:358-60. https://doi.org/10.1111/j.1540-8159.2004.00441.x
  7. Hirsh J, Anand SS, Halperin JL, Fuster V; American Heart Association. Guide to anticoagulant therapy: Heparin: a statement for healthcare professionals from the American Heart Association. Circulation 2001; 103:2994-3018. https://doi.org/10.1161/01.CIR.103.24.2994
  8. Mollmann H, Nef HM, Hamm CW, Elsasser A. How to manage patients with need for antiplatelet therapy in the setting of (un-)planned surgery. Clin Res Cardiol 2009;98:8-15 https://doi.org/10.1007/s00392-008-0718-x
  9. Llau JV, Lopez-Forte C, Sapena L, Ferrandis R. Perioperative management of antiplatelet agents in noncardiac surgery. Eur J Anaesthesiol 2009;26:181-7. https://doi.org/10.1097/EJA.0b013e328324b79f
  10. Phan TG, Koh M, Wijdicks EF. Safety of discontinuation of anticoagulation in patients with intracranial hemorrhage at high thromboembolic risk. Arch Neurol 2000;57:1710-3. https://doi.org/10.1001/archneur.57.12.1710
  11. Marquie C, De Geeter G, Klug D, et al. Post-operative use of heparin increases morbidity of pacemaker implantation. Europace 2006;8:283-7. https://doi.org/10.1093/europace/eul011
  12. Goldstein DJ, Losquadro W, Spotnitz HM. Outpatient pacemaker procedures in orally anticoagulated patients. Pacing Clin Electrophysiol 1998; 21:1730-4. https://doi.org/10.1111/j.1540-8159.1998.tb00271.x
  13. Ahmed I, Gertner E, Nelson WB, et al. Continuing warfarin therapy is superior to interrupting warfarin with or without bridging anticoagulation therapy in patients undergoing pacemaker and defibrillator implantation. Heart Rhythm 2010;7:745-9. https://doi.org/10.1016/j.hrthm.2010.02.018
  14. Cheng A, Nazarian S, Brinker JA, et al. Continuation of warfarin during pacemaker or implantable cardioverter-defibrillator implantation: a randomized clinical trial. Heart Rhythm 2011;8:536-40. https://doi.org/10.1016/j.hrthm.2010.12.016
  15. Daubert JC, Mabo P. Continue or withhold oral anticoagulation in high-risk patients undergoing pacemaker or ICD implantation. Eur Heart J 2009.
  16. Wiegand UK, LeJeune D, Boguschewski F, et al. Pocket hematoma after pacemaker or implantable cardioverter defibrillator surgery: influence of patient morbidity, operation strategy, and perioperative antiplatelet/ anticoagulation therapy. Chest 2004;126:1177-86. https://doi.org/10.1378/chest.126.4.1177
  17. Dreger H, Grohmann A, Bondke H, Gast B, Baumann G, Melzer C. Is antiarrhythmia device implantation safe under dual antiplatelet therapy? Pacing Clin Electrophysiol 2010;33:394-9. https://doi.org/10.1111/j.1540-8159.2009.02645.x
  18. Kutinsky IB, Jarandilla R, Jewett M, Haines DE. Risk of hematoma complications after device implant in the clopidogrel era. Circ Arrhythm Electrophysiol 2010;3:312-8. https://doi.org/10.1161/CIRCEP.109.917625
  19. Tompkins C, Cheng A, Dalal D, et al. Dual antiplatelet therapy and heparin "bridging" significantly increase the risk of bleeding complications after pacemaker or implantable cardioverter-defibrillator device implantation. J Am Coll Cardiol 2010;55:2376-82. https://doi.org/10.1016/j.jacc.2009.12.056
  20. Eisenberg MJ, Richard PR, Libersan D, Filion KB. Safety of short-term discontinuation of antiplatelet therapy in patients with drug-eluting stents. Circulation 2009;119:1634-42. https://doi.org/10.1161/CIRCULATIONAHA.108.813667
  21. Furie B, Furie BC. Mechanisms of thrombus formation. N Engl J Med 2008;359:938-49. https://doi.org/10.1056/NEJMra0801082
  22. Vane JR, Botting RM. The mechanism of action of aspirin. Thromb Res 2003;110:255-8. https://doi.org/10.1016/S0049-3848(03)00379-7
  23. Hirsh J, Dalen J, Anderson DR, et al. Oral anticoagulants: mechanism of action, clinical effectiveness, and optimal therapeutic range. Chest 2001;119(1 Suppl):S8-21.
  24. Grines CL, Bonow RO, Casey DE Jr, et al. Prevention of premature discontinuation of dual antiplatelet therapy in patients with coronary artery stents: a science advisory from the American Heart Association, American College of Cardiology, Society for Cardiovascular Angiography and Interventions, American College of Surgeons, and American Dental Association, with representation from the American College of Physicians. J Am Coll Cardiol 2007;49:734-9. https://doi.org/10.1016/j.jacc.2007.01.003

Cited by

  1. The safety and efficacy of antithrombotic therapy in patients undergoing cardiac rhythm device implantation: a meta-analysis vol.17, pp.7, 2015, https://doi.org/10.1093/europace/euu369
  2. Antithrombotic management in patients undergoing electrophysiological procedures: a European Heart Rhythm Association (EHRA) position document endorsed by the ESC Working Group Thrombosis, Heart Rhyth vol.17, pp.8, 2012, https://doi.org/10.1093/europace/euv190